Archived Transparency
2023 Annual Report
A deep dive into our financial focus for 2023, specifically highlighting Research Grants and new clinical trials funded.
Key Highlights from 2023: Accelerating Research
The year 2023 marked a significant investment into accelerating life-saving research. We allocated a total of **$3.5 million** directly to five new research grants focused on advanced treatments for aggressive prostate cancer. This represents an **18% increase** in direct research funding compared to the previous fiscal year, a major win for the ZERO Initiative community.
-
military_tech
Record Research Funding: $3.5M awarded to genetic and immunotherapy studies.
-
group
Patient Navigator Success: Increased capacity to assist 1,500 new patients with financial and resource navigation.
-
location_on
Screening Events: 85 free prostate cancer screening events held across underserved communities.
Breakdown of Direct Research Investment
| Research Area | Amount Funded |
|---|---|
| Immunotherapy Trials (CAR T-Cell) | $1,500,000 |
| Genetic Biomarker Development | $1,000,000 |
| Active Surveillance Improvement | $500,000 |
| TOTAL DIRECT RESEARCH | $3,000,000 |
Get the Full Document
Download the complete, audited 2023 Annual Report for full financial statements and CEO letter.
picture_as_pdf Download Full PDF (2023)